Kestra Medical Technologies (NASDAQ:KMTS) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Kestra Medical Technologies (NASDAQ:KMTS) from a hold rating to a sell rating in a research report sent to investors on Saturday.

A number of other equities analysts also recently issued reports on the stock. The Goldman Sachs Group cut their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. BTIG Research upped their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday. Finally, Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Stock Up 1.8%

KMTS opened at $24.42 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 7.32. Kestra Medical Technologies has a 12 month low of $14.10 and a 12 month high of $30.00. The stock has a market capitalization of $1.43 billion, a P/E ratio of -10.09 and a beta of 0.47. The business has a 50 day simple moving average of $22.28 and a 200-day simple moving average of $22.72.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. On average, equities analysts anticipate that Kestra Medical Technologies will post -2.3 earnings per share for the current fiscal year.

Insider Activity at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the sale, the insider directly owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Kestra Medical Technologies

Several large investors have recently modified their holdings of KMTS. Russell Investments Group Ltd. lifted its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. grew its holdings in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares in the last quarter. Rhumbline Advisers raised its position in shares of Kestra Medical Technologies by 7.3% in the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Kestra Medical Technologies by 34.6% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after buying an additional 1,392 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.